Together with other studies, TLR3 ligand poly(I:C) seems to be a favorable TLR agonist for DC maturation during antigen loading, which significantly increased the potential for DCexo-induced anti-tumor immunity, and could be employed as a promising maturation stimulus to generate DCexos in future clinical trials. The gene discussed is TLR3; the disease is neoplasm.